Drug repositioning: Identifying and developing new uses for existing drugs

Nature Reviews Drug Discovery

Volumn 3, Issue 8, 2004, Pages 673-683

  Ashburn, Ted T ^a   Thor, Karl B ^a  

^a Dynogen Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; AMFEBUTAMONE; AMLODIPINE; AMLODIPINE PLUS ATORVASTATIN; ATOMOXETINE; ATORVASTATIN; BETA ADRENERGIC RECEPTOR; CELECOXIB; CHLORPROMAZINE; CYCLOOXYGENASE 2; DAPOXETINE; DULOXETINE; FINASTERIDE; FLUOXETINE; GALANTAMINE; GLIBENCLAMIDE PLUS METFORMIN; LOVASTATIN PLUS NICOTINIC ACID; METHYLPHENIDATE; MEVINOLIN; MILNACIPRAN; MINOXIDIL; NICOTINIC ACID; NORADRENALIN; OXYBUTYNIN; ROPINIROLE; SEROTONIN; SIBUT; SIBUTRAMINE; SILDENAFIL; TADALAFIL; TOFISOPAM; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZEPREVE;

ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; BIOTECHNOLOGY; CLINICAL TRIAL; DEPRESSION; DRUG HALF LIFE; DRUG INDUSTRY; DRUG MECHANISM; DRUG RESEARCH; ECONOMIC ASPECT; EJACULATION DISORDER; EPILEPSY; ERECTILE DYSFUNCTION; FIBROMYALGIA; HAIR LOSS; HIGH THROUGHPUT SCREENING; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IRRITABLE COLON; OBESITY; OSTEOARTHRITIS; OVERACTIVE BLADDER; PARKINSON DISEASE; PREMATURE EJACULATION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SMOKING CESSATION; STRESS INCONTINENCE; DRUG DELIVERY SYSTEM; DRUG DESIGN; PHARMACEUTICS; PHARMACOKINETICS;

DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; PHARMACOKINETICS; TECHNOLOGY, PHARMACEUTICAL; THERAPEUTIC EQUIVALENCY;

EID: 4344668661     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1468     Document Type: Review

References (73)

1. Landers, P. Drug industry's big push into technology falls short. Wall Street J. A1 & A8 (2004).
2. Usdin, S. Industry development: pipeline or flatline? BioCentury 1 (2002).
3. Moving beyond the genome projects. Nature Biotechnol. 14, 1234-1238 (1996).
4. Horrobin, D. F. Realism in drug discovery - could Cassandra be right? Nature Biotechnol. 19, 1099-1100 (2001).
5. Editorial. Colonizing therapeutic space: the overlooked science of drug husbandry. Nature Rev. Drug Discov. 3, 101 (2004).
6. Zimmerman, R. New ways to take old drugs help patients extend patents. The Wall Street J. B1 & B3 (2004).
7. Hensley, S. Drug makers' 'combos' treat two disorders with one pill. Wall Street J. B1-B3 (2004).
8. Kerber, R. Old drugs, new life. Boston Globe C1 & C4 (2003).
9. Longman, R. Pharmaceutical strategies: jumpstart to products. In Vivo 22, 17 (2004).
10. Stuart, M. Rediscovering existing drugs. Start-Up 9, 23-30 (2004).
11. Thor, K. B. & Katofiasc, M. A. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J. Pharmacol. Exp. Thera. 274, 1014-1024 (1995).
12. Norton, P. A. Zinner, N. R., Yalcin, I., Bump, R. C. & Duloxetine Urinary Incontinence Study Group. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am. J. Obstet. Gynecol. 187, 40-48 (2002).
13. Lauman, E. O., Paik, A. & Rosen, R. C. Sexual dysfunction in the United States: prevalence and predictors. JAMA 281, 537-544 (1999).
14. PPD. PPD acquires Lilly's patents for dapoxetine; adjusts earnings guidance for 2003 [online], http://www.ppdi.com/PPD_U6.htm?ID=124895 (2003).
15. Ärzteschaft, A. d. D. Der Beitrag der deutschen Ärzteschaft zu verbesserter Arzneimittelsicherheit und rationaler Arzneiverordnung in den achtziger Jahren. 2004, The Contribution of German Physicians to Improved Drug Safety and Rational Drug Regulation in the Eighties (2003).
16. Brynner, R. & Stephens, T. Dark Remedi: The Impact of Thalidomide and Its Revival as a Vital Medicine (Perseus Publishing, Cambridge, 2001).
17. Sampaio, E. P., Sarno, E. N., Galilly, R., Cohn, Z. A. & Kaplan, G. Thalidomide selectively inhibits tumor necrosis factor-α production by stimulated human monocytes. J. Exp. Med. 173, 699-703 (1991).
18. D'Amato, R., Loughnan, M. S., Flynn, E. & Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl Acad. Sci. USA 91, 4082-4085 (1994).
19. Tsao, A. Thalidomide's surprising act IV. Business Week [online] http://www.businessweek.com/technology/content/sep2003/ tc20030924_0938_tc074.htm (2003).
20. Ratner, M. L. Celgene backs into biotech. In Vivo 15, 15 (2001).
21. Celgene. Celgene Corporation reports record operating performance in fourth quarter and full-year 2003 with strong revenue and profit [online], http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol- newsArticle&ID=489440&highlight=2003 (2003).
22. Kolata, G. U. S. approves sale of impotence pill; huge market seen. NY Times (New York) A1 (1998).
23. Haltmaier, H. K., A. Potenz aus dem Labor: Die Erektionspille VIAGRA ('Potency from the Lab: The Erection Pill Viagra') (Rowohlt Taschenbuch Verlag GmbH, Reinbek bei Hamburg, Germany, 1998).
24. Pfizer, Pfizer 8-K filing [online], http://www.pfizer.com/download/investors/financial/8k_0122_04.pdf (2004).
25. Renaud, R. C. & Xuereb, H. Erectile-dysfunction therapies. Nature Rev. Drug Discov. 1, 663-664 (2002).
26. Ostrov, B. F. Renewed life for old drugs. San Jose Mercury News 1E (2004).
27. Thor, K. B. Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction. WO Patent 01/17521 A1 (2001).
28. Rosen, R. C. et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49, 822-830 (1997).
29. SG Cowen. Pharmaceutical Industry Pulse. October (2003).
30. 21 U. S. C. § 355a.
31. 21 CFR 314. 108(b)(4).
32. 21 CFR 314. 108(b)(2).
33. 21 CFR 316. 31.
34. Ratner, M. L. In-licensing: still a difficult model. Start-Up 8, 9-16 (2003).
35. Dawson, H. GSK ventures: recycling R&D assets. In Vivo Europe Rx 2, 30 (2003).
36. Tufts Center for the Study of Drug Development. Outlook 2004 (2004).
37. Gilbert, J., Henske, P & Singh, A. Rebuilding big pharma's business model. In Vivo 21, 73-80 (2003).
38. Stuart, M. Sosei's drug re-profiling strategy: a three-way street. Start-Up 21, 6 (2003).
39. Center for Drug Evaluation and Research. Approval package for Wellbutrin Tablets [online], http://www.fda.gov/cder/foi/nda/96/018644a_s010_s012_s013.pdf (October 31, 1996).
40. GlaxoSmithKline. 1997 Annual Report [online], http://www.gsk.com/financial/financialreports.htm (1998).
41. GlaxoSmithKline. Announcement of 2003 annual results [online], http://www.gsk.com/financial/rpt_q42003.htm (2003).
42. PPD. PPD acquires Lilly's patents for dapoxetine; adjusts earnings guidance for 2003 [online PPD press release], http://www.ppdi.com/PPD_U6.htm?ID=124895 (2003).
43. SG Cowen. Pharmaceutical Industry Pulse. October (2003).
44. Center for Drug Evaluation and Research. CDER new and generic drug approvals: 1998-2004 [online], http://www.fda.gov/cder/approval/index.htm (2004).
45. Eli Lilly. 8-K filing [online], http://www.shareholder.com/Common/Edgar/59478/59478-04-22/04-00.pdf (2004).
46. Parkinson's Information Exchange Network Online. Parkinson's list drug database: chlorpromazine/Thorazine [online], http://www.parkinsons-information-exchange-network-online.com/ drugdb/029.html (2004).
47. Sopharma. Nivalin [online], http://www.bpg.bg/nivalin/default.htm (2004).
48. Janssen Pharmaceuticals. Reminyl consumer home page [online] http://www.us.reminyl.com/ (2004).
49. Pongdee, T., Frigas, E. & Hunt, L. W. Nebulized lidocaine is the drug of choice for severe steroid-dependent asthma. Am. Coll. Allergy Asthma Immunol. Ann. Mtg A50 (2001).
50. Barclay, L. New medical therapy briefs: irritable bowel syndrome [online], http://www.centerwatch.com/bookstore/nmt/nmtb_ibs.pdf (2004).
51. Pfizer. Pfizer 8-K filing [online], http://www.pfizer.com/download/investors/financial/8k_0122_04.pdf (2004).
52. Bacchi, C. J., Nathan, H. C., Hutner, S. H., McCann, P. P. & Sjoerdsma, A. Polyamine metabolism: a potential therapeutic target in trypanosomes. Science 210, 332-334 (1980).
53. Pegg, A. E. Polyamine metabolism and its importance in neoplastic growth as a target for chemotherapy. Cancer Res. 48, 759-774 (1988).
54. CenterWatch. Newly Approved Drugs - Propecia (Merck). [online] http://www.centerwatch.com/patient/drugs/dru371.html (2004).
55. Merck & Co. Other financial disclosures, fourth quarter 2003 [online], http://media.corporate-ir.net/media_files/irol/73/73184/ reports/4q03disclosures.pdf (2004).
56. Erickson, D. Emerging company profile: Pharmagene PLC. Start-Up September 23-28 (1999).
57. Resource Informagen. Pharmacia & Upjohn, Inc. [online], http://informagen.com/Resource_Informagen/Deprecated/6/3436.php (2004).
58. Pharmacia & Upjohn. Hair loss news: FDA Advisory Committee recommends rogaine extra strength for OTC sales [online press release], http://www.regrowth.com/hair_loss_treatments/minoxidil_rogaine/ rogaine_extra_strength_approval.cfm (July 27, 1997).
59. Pierson, R. Merck hair-loss pill seen as future blockbuster. Indian Express (Bombay) (24 Dec 1997).
60. 2 paclitaxel-eluting coronary stent system [online press release], < http://www.bostonscientific.com/common_templates/articleDisplayTemplate. jhtml?task=tskPressRelease.jhtml§ionld=2&relld=24, 25&uniqueld=ABPR4584&clickType=endeca&acceptedWarning=PR (4 March 2004).
61. Boston Scientific. 8-K filing [online] http://ccbn.tenkwizard.com/filing.php?repo=tenk&ipage=2737693&doc =1&total=&attach=ON&TK-BSX&CK=0000885725& CN=Boston+Scientific+ Corporation&FG=0&CK2=885725& FC-000000&BK=FFFFFF&SC=ON&TC- FFFFFF&TC1=FFFFFF& TC2=FFFFFF&LK=0000FF&AL=FF0000&VL=800080 (2004).
62. Longman, R. Jumpstart to products. In Vivo February 17-30 (2004).
63. Eli Lilly. January 29, 2004 8-K. Indianapolis: Eli Lilly, 2004. http://www.shareholder.com/Common/Edgar/59478/59478-04-22/04-00.pdf, accessed February 13, 2004.
64. Icos Corp. ICOS Corporation reports results for 2003 [online press release], http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=ICOS&script= 410&layout=0&item_id=491321 (3 Feb 2004).
65. Celgene Pharmaceuticals. Thalomid history [online], http://www.celgene.com/thalomid/ (2004).
66. Celgene Pharmaceuticals. Celgene Corporation reports record operating performance in fourth quarter and full-year 2003 with strong revenue growth and profits [online press release], http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol- newsArticle&ID=489440&highlight=full-year%202003 (29 Jan 2004).
67. Cypress Bioscience. Fribromyalgia syndrome: minacipran Phase III trial [online], http://www.cypressbio.com/corp/products/fms/phaseIII.jsp (2004).
68. Ratner, S. Sention Inc: improving memory consolidation. Start-Up November 34-36 (2002).
69. Biomedicines. Products [online], http://www.biomedicinesinc.com/products.htm (2004).
70. ChemGenex. Quinamed [online], http://www.chemgenex.com/quinamed.php (2004).
71. ChemGenex. Quinamed [online], http://www.chemgenex.com/ceflatonin.php (2004).
72. Reichert, J. M. Trends in development and approval times for new therapeutics in the United States. Nature Rev. Drug Discov. 2, 695-702 (2003).
73. Women's Health Action Trust. Events report: RU486 seminar [online], http://www.womens-health.org.nz/events/RU486.htm (2000).